Aitziber Buqué
Aitziber Buqué
Gustave Roussy Cancer Campus; INSERM , U1138; Equipe 11 labellisée par la Ligue Nationale contre le
Verified email at inserm.fr
TitleCited byYear
Immunological effects of conventional chemotherapy and targeted anticancer agents
L Galluzzi, A Buque, O Kepp, L Zitvogel, G Kroemer
Cancer cell 28 (6), 690-714, 2015
4172015
Immunogenic cell death in cancer and infectious disease
L Galluzzi, A Buqué, O Kepp, L Zitvogel, G Kroemer
Nature Reviews Immunology 17 (2), 97, 2017
4022017
Consensus guidelines for the detection of immunogenic cell death
O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ...
Oncoimmunology 3 (9), e955691, 2014
3242014
Classification of current anticancer immunotherapies
L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buque, L Senovilla, ...
254*
Trial watch: oncolytic viruses for cancer therapy
J Pol, N Bloy, F Obrist, A Eggermont, J Galon, I Cremer, P Erbs, ...
Oncoimmunology 3 (6), e28694, 2014
1562014
Caloric restriction mimetics enhance anticancer immunosurveillance
F Pietrocola, J Pol, E Vacchelli, S Rao, DP Enot, EE Baracco, S Levesque, ...
Cancer cell 30 (1), 147-160, 2016
1332016
Trial Watch: Peptide-based anticancer vaccines
J Pol, N Bloy, A Buqué, A Eggermont, I Cremer, C Sautes-Fridman, ...
Oncoimmunology 4 (4), e974411, 2015
792015
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
A Buqué, N Bloy, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (4), e1008814, 2015
672015
Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy
K Iribarren, N Bloy, A Buqué, I Cremer, A Eggermont, WH Fridman, ...
562015
eIF2α phosphorylation as a biomarker of immunogenic cell death
O Kepp, M Semeraro, JM Bravo-San Pedro, N Bloy, A Buqué, X Huang, ...
Seminars in cancer biology 33, 86-92, 2015
462015
Trial Watch: Immunotherapy plus radiation therapy for oncological indications
E Vacchelli, N Bloy, F Aranda, A Buqué, I Cremer, S Demaria, ...
Oncoimmunology 5 (9), e1214790, 2016
432016
Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
A Buqué, N Bloy, F Aranda, I Cremer, A Eggermont, WH Fridman, ...
Oncoimmunology 5 (6), e1149674, 2016
372016
Trial Watch—Immunostimulation with cytokines in cancer therapy
E Vacchelli, F Aranda, N Bloy, A Buqué, I Cremer, A Eggermont, ...
Oncoimmunology 5 (2), e1115942, 2016
302016
Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells
A Buqué, JS Muhialdin, A Muñoz, B Calvo, S Carrera, U Aresti, A Sancho, ...
Molecular cancer 11 (1), 25, 2012
292012
Trial watch: Naked and vectored DNA-based anticancer vaccines
N Bloy, A Buqué, F Aranda, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (5), e1026531, 2015
262015
Trial Watch: Adoptive cell transfer for oncological indications
F Aranda, A Buqué, N Bloy, F Castoldi, A Eggermont, I Cremer, ...
Oncoimmunology 4 (11), e1046673, 2015
242015
Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies
S Carrera, A Buque, E Azkona, U Aresti, B Calvo, A Sancho, M Arruti, ...
Clinical and Translational Oncology 16 (4), 339-350, 2014
242014
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance
N Bloy, P Garcia, CM Laumont, JM Pitt, A Sistigu, G Stoll, T Yamazaki, ...
Immunological reviews 280 (1), 165-174, 2017
192017
Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells
A Buqué, U Aresti, B Calvo, JS Muhialdin, A Muñoz, S Carrera, E Azkona, ...
PloS one 8 (5), e63338, 2013
162013
The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ
M Semeraro, J Adam, G Stoll, E Louvet, K Chaba, V Poirier-Colame, ...
Oncoimmunology 5 (10), e1218106, 2016
152016
The system can't perform the operation now. Try again later.
Articles 1–20